DHA Supplementation in Preterm Infants Boosts Blood Fatty Acid Levels, Study Finds

A new study published in Pediatric Research on June 5, 2026, explores how enteral DHA supplementation affects blood fatty acid levels in preterm infants. The findings reveal significant increases in DHA concentrations, offering potential benefits for neurodevelopment and inflammation control.

The research focused on preterm infants receiving docosahexaenoic acid (DHA) through enteral feeding. Unlike parenteral methods, this approach proved both practical and well-tolerated in the fragile neonatal group. Blood tests confirmed that DHA levels rose substantially in supplemented infants compared to those in the control group.

The elevated DHA concentrations remained stable throughout the monitoring period, suggesting lasting neurodevelopmental support. Beyond raising DHA, the supplementation altered the balance of omega-6 to omega-3 fatty acids, which may help reduce chronic inflammation and improve clinical outcomes. Further analysis showed shifts in other fatty acid subsets, highlighting DHA’s complex role in lipid metabolism. The study also controlled for confounding variables, reinforcing the reliability of the results and their potential application in clinical settings. Detailed fatty acid profiling provided new insights into how preterm infants process lipids, supporting the idea of tailored neonatal nutrition. DHA’s benefits extend beyond brain structure, as it also serves as a precursor for anti-inflammatory compounds. This dual role—structural and metabolic—could enhance cerebral substrate availability, possibly influencing long-term cognitive and sensory development.

The study confirms that enteral DHA supplementation boosts blood DHA levels in preterm infants while maintaining stability over time. These findings point to broader implications for neonatal nutrition, inflammation management, and neurodevelopmental outcomes. The results may guide future clinical strategies for preterm care.